Pituitary gigantism: a retrospective case series

Area of Science:

• Pediatric Endocrinology
• Oncology
• Neurosurgery

Background:

• Pituitary gigantism (PG) is a rare pediatric endocrine disorder with unclear long-term outcomes.
• Characterized by excessive growth due to growth hormone (GH) hypersecretion, often from pituitary adenomas.
• Limited data exists on the comprehensive clinical course and treatment efficacy in pediatric PG patients.

Purpose of the Study:

• To describe the longitudinal clinical course of pediatric patients diagnosed with pituitary gigantism.
• To evaluate the effectiveness of various treatment modalities in managing GH levels and tumor control.
• To compare treatment outcomes in pediatric PG with those reported for adult populations.

Main Methods:

• Retrospective cohort study of patients under 19 years diagnosed with PG.
• Inclusion criteria: histopathological confirmation of GH-secreting adenoma/hyperplasia and height >2 SD.
• Data abstracted included laboratory results, pathology, imaging, and treatment history.

Main Results:

• Average age at diagnosis was 13 years; average tumor size was 7.4×3.8 mm.
• Initial transsphenoidal surgery was curative in only 3 of 12 patients; repeat surgery was rarely successful.
• Medical therapies (octreotide, pegvisomant) and radiation had limited success rates in refractory cases.

Conclusions:

• Pituitary gigantism in children presents significant treatment challenges.
• Surgical and medical interventions demonstrate suboptimal efficacy in normalizing GH levels and achieving long-term remission.
• Pediatric PG treatment outcomes may differ from adult PG, necessitating further investigation and tailored therapeutic strategies.